Zhongzheng Intelligent Finance and HUTCHMED (00013) announced on November 27th in the morning that the latest and updated data of several of the company's independently developed compounds will be presented at the ESMO Asia Annual Meeting to be held in Singapore from December 5th to 7th, 2025, and at the American Society of Hematology (ASH) Annual Meeting to be held in Orlando, USA from December 6th to 9th.

Specifically, the first human clinical trial results of the anti-CD47 monoclonal antibody HMPL-A83 for the treatment of advanced solid tumors, as well as the results of the II phase part of the FRUSICA-2 registration study of the combination of fuyiquitini and xindili monoclonal antibody for second-line treatment of locally advanced or metastatic renal cell carcinoma, will be announced at the ESMO Asia Annual Meeting; the results of the II phase part of the II/III phase study of sorvatinib combined with carlimilizumab and chemotherapy for first-line treatment of metastatic pancreatic cancer will also be announced at the conference.

The announcement shows that fuyiquitini is a selective oral VEGFR inhibitor, which is jointly developed and commercialized by HUTCHMED and Eli Lilly in China, and Takeda has the global exclusive license for it; HMPL-A83 is a research-oriented anti-CD47 monoclonal antibody, and Huangyao Pharmaceutical owns all the rights to it worldwide; Savoritini is an oral MET tyrosine kinase inhibitor, developed by AstraZeneca and Huangyao Pharmaceutical together; Sorvatinib is an oral tyrosine kinase inhibitor with dual anti-angiogenic and immunomodulatory activities, and Huangyao Pharmaceutical owns all the rights to it worldwide; Solupinib is an exploratory oral Syk inhibitor, and Huangyao Pharmaceutical retains all the rights to it worldwide.

HUTCHMED is a commercial-stage innovative biopharmaceutical company dedicated to discovering, developing, and commercializing targeted drugs and immunotherapies for the treatment of cancer and immune diseases. Currently, three of its drugs have been approved for sale in China, and the first drug has also been approved in the United States, Europe, and Japan.

https://finance.eastmoney.com/a/202511273576302819.html